이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

재발성/불응성 변연부 림프종 환자를 위한 모수네투주맙과 자누브루티닙의 2상 시험

2026년 9월 30일 업데이트: M.D. Anderson Cancer Center

To assess the efficacy and safety of mosunetuzumab combined with zanubrutinib in patients with relapsed or refractory MZL.

연구 개요

상세 설명

Primary Objectives:

To determine the safety and efficacy of mosunetuzumab in combination with zanubrutinib as determined by best complete response (CR) rate of combination treatment for patients with relapsed or refractory marginal zone lymphoma (MZL).

Secondary Objectives:

To determine best overall response rate (ORR), duration of response (DOR), time to next treatment, progression-free survival (PFS), overall survival (OS), and evaluation of tolerability of mosunetuzumab and zanubrutinib as treatment for patients with relapsed/refractory MZL.

Exploratory Objective:

To determine the impact of total metabolic tumor volume to ORR, CR rate and survival outcomes

To determine the biomarkers that correlates with response and mechanisms of resistance to mosunetuzumab and zanubrutinib in relapsed/refractory MZL.

To determine the surrogate endpoint for future trials in MZL.

연구 유형

중재적

등록 (추정된)

36

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Texas
      • Houston, Texas, 미국, 77030
        • 모병
        • MD Anderson Cancer Center
        • 연락하다:
        • 수석 연구원:
          • Dai Chihara, MD,PHD

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

Patients must meet the following criteria for study entry:

  1. Histologically diagnosed marginal zone lymphoma (any subtypes)

    o Low grade or indolent B-cell lymphoma unclassifiable is also eligible

  2. Have received at least 1 prior treatment including CD20 monoclonal antibody

  3. Patients have relapsed or refractory disease to their most recent regimen

  4. Stage II, III or IV disease

  5. Age ≥18 years. Because no dosing or adverse event data are currently available on the use of mosunetuzumab and zanubrutinib combination in patients <18 years of age, children are excluded from this study.

  6. Performance status ≤2 on the ECOG scale (≤3 if due to lymphoma)

  7. Requiring systemic therapy assessed by investigator based on tumor size, symptoms and/or GELF criteria

    • A nodal or extranodal (except spleen) mass > 7 cm in its greater diameter

    • At least 3 nodal or extranodal sites ≥ 3 cm in diameter

    • Presence of at least one B symptom

    • Fever (>38 C), night sweats, weight loss > 10% in the past 6 months

    • Symptomatic splenomegaly (or size >13cm)

    • Impending organ compression or involvement (ureteral, orbital, gastrointestinal)

    • Any of the following cytopenias due to bone marrow involvement of lymphoma

      • Hemoglobin ≤ 10 g/dL
      • Platelets ≤ 100 x 109/L
      • Absolute neutrophil count (ANC) < 1.5x109/L
    • Pleural effusion or ascites

    • LDH > ULN or β2 microglobulin > ULN

  8. Bi-dimensionally measurable disease, with at least one nodal lesion ≥ 1.5 cm or one extra-nodal lesion > 1 cm in longest diameter by CT, PET/CT, and/or MRI

    • Subjects with splenic MZL who do not meet the radiographically measurable disease criteria are eligible for participation if spleen is enlarged over 16 cm and MZL is histologically confirmed by bone marrow biopsy or peripheral blood flow cytometry
    • Subjects with EMZL such as skin of conjunctival EMZL who do not meet the radiographically measurable disease criteria are eligible for participation if at least one of the skin lesions is histologically confirmed as MZL and measures ≥1.5 cm in diameter
  9. Patients must have adequate organ and marrow function as defined below:

    • Total bilirubin ≤ 1.5 institutional ULN, unless consistent with Gilbert's (ratio between total and direct bilirubin > 5)

    • AST (SGOT) and ALT (SGPT) ≤ 3 x institutional ULN

    • Alkaline phosphatase < 2.5 ULN

    • Creatinine clearance ≥ 40 ml/min calculated by modified Cockcroft-Gault formula

    • Blood counts below if without lymphoma cause for cytopenia

    • Hemoglobin ≥ 8 g/dL

    • Platelets ≥ 75 x 109/L

    • Absolute neutrophil count (ANC) ≥ 1.0x109/L

    • Blood counts below if cytopenia are due to lymphoma (such as bone marrow involvement or splenomegaly)

      • Hemoglobin ≥ 6 g/dL (no transfusion within 7 days prior to treatment)
      • Platelets ≥ 50 x 109/L
      • Absolute neutrophil count (ANC) ≥ 0.5x109/L

Exclusion Criteria:

Subjects will be ineligible for this study if they meet any of following criteria:

  1. Known active central nervous system lymphoma or leptomeningeal disease.

  2. Treatment with any chemotherapeutic agent, or treatment with any other anti-lymphoma agent (investigational or otherwise) within 4 weeks or five half-lives of the drug, whichever is shorter, prior to first investigational agent administration.

  3. Any prior history of other malignancy besides B-NHL, unless the patient has been free of disease for ≥ 1 year and felt to be at low risk for recurrence by the treating physician, except:

    • Adequately treated localized skin cancer without evidence of disease.
    • Adequately treated or monitored low risk localized prostate cancer.
    • Adequately treated localized breast cancer without evidence of disease.
    • Adequately treated cervical carcinoma in situ without evidence of disease.
  4. Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of lenalidomide capsules, or put the study outcomes at undue risk.

  5. Uncontrolled human immunodeficiency virus (HIV), or active Hepatitis C Virus, or active Hepatitis B Virus infection, or any uncontrolled active significant infection, including suspected or confirmed JC virus infection and SARS-CoV2.

  6. Patients with inactive hepatitis B infection must adhere to hepatitis B reactivation prophylaxis unless contraindicated. Hepatitis B or C serologic status: subjects who are hepatitis B core antibody (anti-HBc) positive and who are surface antigen negative will need to have a negative polymerase chain reaction (PCR). Those who are hepatitis B surface antigen (HBsAg) positive or hepatitis B PCR positive will be excluded. Subjects who are hepatitis C antibody positive will need to have a negative PCR result. Those who are hepatitis C PCR positive will be excluded. Subjects with a history of Hepatitis C who received antiviral treatment are eligible as long as PCR is negative.

  7. History of immunodeficiency (with the exception of hypogammaglobulinemia) or concurrent systemic immunosuppressant therapy (e.g., cyclosporine, tacrolimus, etc., or chronic administration glucocorticoid equivalent of >10mg/day of prednisone) within 28 days of the first dose of study drug with exception of steroid used for IV contrast allergy. In addition, use of inhaled, topical, intranasal corticosteroids or local steroid injection (eg, intra- articular injection) is permitted.

  8. Use of strong/moderate inhibitors within 7 days or 5 half-lives prior to the first dose of zanubrutinib; usage of strong/moderate CYP3A inducers within 14 days prior to the first dose of zanubrutinib.

  9. Requiring ongoing therapy with strong or moderate CYP3A inducers.

  10. Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification. Subjects with controlled, asymptomatic atrial fibrillation during screening can enroll on study.

  11. Significant screening electrocardiogram (ECG) abnormalities including 2nd degree atrioventricular (AV) block, type II AV block, or 3rd degree block.

  12. Active bleeding or known bleeding diathesis (e.g., von Willebrand's disease) or hemophilia.

  13. History of stroke or intracranial hemorrhage within 6 months prior to study entry.

  14. Lactating or pregnant subjects.

  15. Administration of any investigational agent within 28 days of first dose of study drug.

  16. Patients who have undergone major surgery within 28 days or minor surgery within 3 days of first dose of study drug.

  17. Patients taking corticosteroids during the last 4 weeks, unless administered at a dose equivalent to < 10 mg/day prednisone (over these 4 weeks) with the exception of pre-study steroid treatment with prednisone up to 100mg x 5 days which is allowed to improve symptoms and treatment tolerance.

  18. Known or suspected chronic active Epstein-Barr virus (CAEBV) infection

  19. Administration of a live, attenuated vaccine within 4 weeks before first mosunetuzumab administration or anticipation that such a live, attenuated vaccine will be required during the study.

  20. Prior solid organ transplantation

  21. Prior allogeneic stem cell transplant (autologous stem cell transplants are allowed if conducted at least 100 days prior to C1D1.)

  22. Contraindication to tocilizumab

  23. Patients who have difficulty with or are unable to swallow oral medication, or have disease significantly affecting gastrointestinal function that would limit absorption of oral medication.

  24. Patients who have an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.

  25. Patients who have a history of (non-infectious) autoimmune pneumonitis that required steroids or has current autoimmune pneumonitis.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: 모수네투주맙 + 자누브루티닙 병용 치료

Given by IV

다른 이름들:
  • RO7030816

Given by IV

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Safety and Adverse Events (AEs)
기간: Through study completion; an average of 1 year.

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Through study completion; an average of 1 year.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Dai Chihara, MD,PHD, M.D. Anderson Cancer Center

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 12월 11일

기본 완료 (추정된)

2026년 12월 31일

연구 완료 (추정된)

2028년 12월 31일

연구 등록 날짜

최초 제출

2024년 8월 19일

QC 기준을 충족하는 최초 제출

2024년 8월 19일

처음 게시됨 (실제)

2024년 8월 20일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 30일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 2024-0243
  • NCI-2024-06965 (기타 식별자: NCI-CTRP Clinical Trial Registry)

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다